Rachel Abbott
Chief Executive Officer Pan Cancer T
Rachel Abbott is Chief Executive Officer of Pan Cancer T, having joined the company in January 2023 as Chief Scientific Officer and assuming the CEO role in May 2023. She brings extensive expertise in TCR-T cell therapies, developed through industry leadership roles at Adaptimmune and Enara Bio. Her work has spanned TCR discovery, affinity-engineered T cell pipelines, large-scale T cell manufacturing, and advancement of programs targeting PRAME and NY-ESO. Rachel holds a DPhil and MBiochem from the University of Oxford and completed postdoctoral training at the University of Birmingham.
Seminars
Wednesday 16th September 2026
Next-Generation TCR Engineering: Integrating Co-Stimulation & Novel Antigen Targeting to Expand the Reach of T-Cell Therapies
11:15 am
- Engineering next generation TCR constructs with built in co-stimulatory signaling to deliver dual functionality through a single molecule
- Reducing reliance on additional receptors, knockouts, or complex modifications to improve manufacturability and clinical durability
- Targeting novel solid tumor antigens such as ROPN1 in triple negative breast cancer to address high unmet need and expand the reach of T-cell therapies into new indications
